Accelerating the future of protein therapeutics
Computational protein design and AI accelerate biologics development — from antibodies to enzyme replacement therapies. Arzeda partners with Takeda on protein-therapeutic optimization programs.
The Challenge
What partners are up against
Developing protein-based therapeutics is slow, expensive, and high-risk. Traditional discovery methods rely on screening vast libraries of variants, with success rates that leave enormous room for improvement.
Our Approach
How Arzeda delivers
Arzeda's platform computationally designs optimized protein therapeutics with specific functional properties. Physics-based computation plus AI trained on 15+ years of proprietary protein data accelerates the path from target to candidate — delivered into partner programs end-to-end.
Case study & results
Arzeda is collaborating with Takeda to accelerate protein-biologics optimization using our computational design platform. Public details to follow as the partnership reaches commercial milestones.